Daratumumab for refractory aplastic anemia
Treatments studied
Part of Blood & lymphatic clinical trials.
This trial tests a drug called daratumumab for people with aplastic anemia that hasn't improved with standard treatments. The goal is to see if it can help your bone marrow make more blood cells and improve your blood counts.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have aplastic anemia that has not responded to at least 6 months of standard treatments (like cyclosporine and eltrombopag).
- You have low blood counts (hemoglobin below 90 or platelets below 30).
- You are not eligible for or do not want a stem cell transplant.
- You are in generally good health (able to do daily activities with some help if needed).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new antibody drug (anti-CD38) for people with severe aplastic anemia that has not responded to or has come back after standard treatments. The goal is to see if this drug can help improve blood counts when other options have failed.
This trial tests a new treatment called CD7 car-t cells (rd13-02) for people with severe aplastic anemia that has not responded to standard therapy or has come back. The goal is to see if this therapy can help restore normal blood cell production.
This study tests a new medicine called CM313 for people with aplastic anemia that has not responded to standard treatments or has come back. The medicine is given as an injection under the skin and may help your bone marrow make more blood cells.
This trial tests a new combination of a targeted drug (daratumumab) plus chemotherapy, followed by a stem cell transplant, for people with a rare and aggressive blood cancer called primary plasma cell leukemia. The goal is to see if adding daratumumab improves the chances of getting rid of the cancer and staying in remission.
This Phase 1 study tests a targeted radioactive medicine made from daratumumab plus a radioactive payload, aiming to treat multiple myeloma that has come back or doesn’t respond to treatment. It’s designed mainly to check safety and how the treatment works in people who have had several prior therapies.
This trial tests the drug daratumumab in people newly diagnosed with light chain amyloidosis that affects the heart, kidney, or liver. The goal is to see if daratumumab can help control the disease. Eligibility depends on your disease stage and overall health.
Hear when a new Aplastic Anemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.